Audit of a monitoring service for free phenytoin
|
|
- Tamsin Haynes
- 6 years ago
- Views:
Transcription
1 Br. J. clin. Pharmac. (1985), 19, Audit of a monitoring service for free phenytoin G. M. PETERSON, S. McLEAN, 2R. J. von WITT & 'K. S. MILLINGEN School of Pharmacy and 'Department of Medicine, University of Tasmania, Hobart, and 2Department of Clinical Chemistry, Royal Hobart Hospital, Tasmania, Australia This study assessed the value of introducing the measurement of free phenytoin levels in a public hospital. After publicising the availability and purpose of the assay, free phenytoin levels were determined either (a) on the doctor's request or (b) when the total level was requested and the patient's record showed evidence of factors predisposing to an elevated unbound fraction. Total phenytoin was measured by EMIT, and the unbound fraction by ultrafiltration at 37 C using [14C]-phenytoin as a tracer. During a 9 month period, 70 free level determinations were performed on 46 patients. These comprised 20% of all phenytoin assays. The median free phenytoin fraction was 13.6% (range %). While total phenytoin levels were below the normal optimum range in 61% cases, free levels were probably therapeutic or above in 70% cases. Dosage adjustments were recommended on the basis of the free level, and were followed more often when the doctor had requested the free level assay (P < 0.05). The results suggest that a free phenytoin level assay can improve the usefulness of therapeutic drug monitoring, particularly when the doctor understands the purpose of the assay. Keywords phenytoin monitoring service Introduction While total plasma levels of phenytoin are routinely used to measure dosage-effectiveness, they only provide a reliable predictor of the anticonvulsant effect if the variation between patients in the unbound (free) plasma fraction of phenytoin is small. The variation is certainly small in vitro using plasma from healthy subjects (Yacobi et al., 1977) and in otherwise healthy epileptic patients, who infrequently receive displacing drugs (Rimmer et al., 1984). As noted by Perucca (1984), however, in practice a considerable number of patients receiving phenytoin have an impairment in plasma protein binding of the drug for various reasons: renal or hepatic disease, old age, late pregnancy, any condition associated with hypoalbuminaemia, and concomitant interacting drugs including sodium valproate, phenylbutazone, sulphonamides, and salicylates. We have previously shown that about 20% of epileptic patients receiving phenytoin have elevated unbound plasma fractions of the drug because of the factors listed above (Peterson et al., 1982). Other workers have also reported considerable variability in the unbound phenytoin fraction in epileptic patients (Walther & Meyer, 1979; DeMonaco & Lawless, 1983; Kilpatrick et al., 1984). Hence, phenytoin fulfills the three criteria proposed by Levy & Moreland (1984) for the consideration of routine measurement of free drug levels: the usefulness of total plasma level monitoring has been Correspondence: Dr G. M. Peterson, School of Pharmacy, University of Tasmania, PO Box 252C, Hobart 7001, Tasmania, Australia 693
2 694 G. M. Peterson et al. established, the drug is highly (about 90%) bound to plasma proteins, and it exhibits a variable unbound fraction. This study sought to test the value of introducing a free phenytoin level monitoring service at the Royal Hobart Hospital, a 600-bed public hospital. Methods The availability and purpose of the free phenytoin level assay were firstly publicised verbally and in a newsletter which is regularly distributed throughout the Royal Hobart Hospital. Unbound phenytoin fractions in plasma were then determined when either: (a) determination of the free phenytoin level was specifically requested by a doctor, or (b) determination of the total phenytoin level was requested, and the request form or patient's clinical chemistry record indicated factors which could cause an elevated unbound fraction of the drug. The unbound fraction of phenytoin was determined by ultrafiltration with the Amicon MPS-1 micropartition system using YMT ultrafiltration membranes (Kilpatrick et al., 1984), at 37 C. Radioactive 5,5-diphenyl-4-[14C]- hydantoin] of > 98% purity (New England Nuclear) was added to the plasma sample as a tracer. The unbound fraction was calculated by dividing the disintegrations per minute (d/min) in 0.1 ml ultrafiltrate by the d/min in the same volume of plasma before ultrafiltration. The coefficient of variation of the method for repeated measurements on fresh plasma containing 60 pumol/l phenytoin was 4.9% (n = 6). Total phenytoin concentrations in plasma were determined by EMIT (Syva, Palo Alto, Ca, USA), and free phenytoin concentrations were calculated from the total concentration and unbound fraction. Each patient's anticipated optimum range of total phenytoin in plasma was estimated by multiplying the normal optimum range (40-80,mol/l) by the normal value for unbound fraction of phenytoin (0.10)/ observed value. The results were presented as shown in Figure 1, and communicated to the particular hospital ward or clinic. The action taken on the basis of the results sheet was then determined by examining each patient's medical record, generally 1-2 weeks later. An albumin level (bromocresol green dyebinding method using a Technicon SMA II) and immunospecific albumin level (immunonephelometric method using a Beckman ICS analyser II) were also determined in most plasma samples. Results Over a 9 month period, 70 free phenytoin level assays were performed. These comprised 20% of all phenytoin assays. The 70 assays involved 46 patients (24 female, 22 male) aged 1 to 86 years (median 51 years). Reasons for performing the assay are listed in Table 1. The most common displacing drug was sodium valproate (13 assays). Doctors were apparently unaware of the assay's potential usefulness in elderly or pregnant patients receiving phenytoin. The unbound phenytoin fractions ranged from 9.3 to 28.6%, with a median value of 13.6%. The total phenytoin concentration was within the normal optimum range (40-80,umol/ 1) in only 21 (30%) of the cases, and below this range in 43 (61%) cases. However, if one compares the free levels found with the expected optimum range for free phenytoin (40-80,umol/l x 0.10 = 4-8,umol/l), most results were either within (49%) or above (21%) this range. Hence, use of the total phenytoin assay indicated that most patients needed increases in dosage, whereas the free phenytoin assay level showed that most patients probably required no alteration in dosage, or even a reduction. Follow-up showed that the actual dosage adjustments made were in accordance with the recommendation in all cases (15) when the free phenytoin assay had been specifically requested by the patient's doctor. However, recommendations following laboratory-initiated free level assays were apparently followed in only 41 out of 55 (75%) cases. This difference in the implementation of results ordered by the doctor and those initiated by the laboratory was statistically significant (chi-square = 4.77, 1 df, P < 0.05). These analyses include cases where the dosage adjustment recommendation is the same based on the total and free phenytoin level. To determine whether the total or free phenytoin levels were used when contemplating a dosage adjustment, one has to examine the subset of samples where the dosage adjustment recommendations differ. In practice, this arose in one of two situations: (a) when the free level was within the anticipated optimum range of 4-8,umol/l, but the total level was below the normal optimum range of 40-80,umol/l (recommended no change in dosage), or (b) when the free level was above 8,umol/l, but the total level was within or below the 40-80
3 Results sheet Short report 695 Name XSXXXXXXXXXXXX.... Number.. X... Date. 8/2184. Phenytoin is normally highly (90%) bound to plasma albumin. Only the unbound or free fraction of phenytoin in plasma has anticonvulsant activity. The commonly stated therapeutic range of phenytoin in plasma (40 to 80 pmol/l refers to the total phenytoin level and assumes that the extent of phenytoin binding to plasma albumin varies little between patients. However, the free fraction of phenytoin in plasma can be greatly increased in certain circumstances (e.g. treatment with interacting drugs such as sodium valproate, aspirin, warfarin, and phenylbutazone; pregnancy; hyperthyroidism; liver disease; and renal failure). When the phenytoin free fraction is elevated, the patient has a lower than normal therapeutic range for phenytoin, and toxicity may appear at total phenytoin levels normally within the therapeutic range. This patient has/is reeeiving... which can increase the free fraction of phenytoin in plasma. We have determined this patient's free phenytoin fraction in plasma, and the results follow. Total phenytoin concentration (omol/l) Therapeutic range, in patients with normal plasma protein binding (pmol/l) Percentage of phenytoin free in plasma (normally about 10%) Free phenytoin concentration (pmol/l) Therapeutic range for free phenytoin (pmol/l) Anticipated therapeutic range for total phenytoin in this patient (pmol/l) Suggested change to phenytoin dosage based on assay results Figure 1 Example of free phenytoin level results sheet change no iecrease deereaee Table 1 Reasons for performing the free phenytoin level assay Number of assays Assay performed on: Reason Doctor's request Laboratory initiative Renal failure 2 3 Hepatic disease 5 4 Hypoalbuminaemia 4 10 Pregnant/post-partum 0 7 Age over 65 years 0 16 Displacing drug 2 15 Persistently low total 2 0 levels 15 55
4 696 G. M. Peterson et al.,umol/l range (recommended a reduction in dosage). In this subset of samples, the dosage adjustment recommendation based on the free level was followed in all seven cases when the doctor specifically requested the assay, but was followed in only 50% (11 of 22) cases when the assay was initiated by the laboratory. This difference was statistically significant (chi-square = 5.64, 1 df, P < 0.05). There was a moderate correlation between the unbound phenytoin fraction and the plasma albumin level measured by the routine dyebinding method (n = 54, r = -0.70, P < 0.001). A stronger correlation existed with the plasma albumin level measured by the immunospecific method (n = 65, r = -0.80, P < 0.001). There was a reasonably strong correlation between plasma albumin levels measured by the two methods (n = 52, r = 0.87, P < 0.001). The mean albumin level was 37.3 g/l (s.d. 5.7) with the dye-binding method, and 35.8 g/l (s.d. 9.1) with the immunospecific method. Discussion The results of our previous study (Peterson et al., 1982) indicated that the unbound fraction of phenytoin in plasma is elevated (> 14.5% unbound) in as many as one in five epileptic patients. This proportion was doubled in the present study, principally due to the selection criteria used. This study shows that in the subgroup of patients with abnormal phenytoin binding, use of a free phenytoin assay can improve the value of therapeutic drug monitoring as a measure of dosage-effectiveness. This was illustrated by the finding that, amongst the patients selected, total phenytoin levels were below the normal optimum range in 61% cases, while free levels were probably therapeutic or above in 70% cases. In most cases, the free level was apparently used in preference to the total level when considering dosage adjustments of phenytoin. This was more likely when doctors specifically requested the free level assay and, presumably, therefore understood its pharmacological basis, than when doctors received unrequested advice from the monitoring service. Clearly, to rationally apply a new assay's result, the doctor must understand the purpose of the assay. It should be recognised, however, that the statistical analyses did not take into account the clinical status of each patient when considering a dosage adjustment of phenytoin. Furthermore, there was no attempt in this study to determine the influence of monitoring free phenytoin levels on the clinical control of patients. Additional clinical research is obviously required, for instance, to confirm that the optimum range of free phenytoin concentrations in plasma matches that extrapolated from the total concentrations. A free phenytoin level assay performed after the audit period further illustrates the clinical usefulness of the assay. A 55 year old female patient with renal failure due to chemotherapy for multiple myeloma (serum creatinine 444,umol/l; albumin 16 g/l by dye-binding method, 11 g/l by immunospecific method) was receiving 500 mg phenytoin daily. She was in a semiconscious state and having generalized major seizures. Her total phenytoin level was only 57,umol/l, but the unbound fraction was 42% and the free level 24,u mol/l, well above the expected optimum range. Her phenytoin was ceased, but she died 2 days later when peritoneal dialysis was discontinued. Finally, our results indicate that plasma albumin levels measured by an immunospecific assay provide a better indicator of phenytoin binding capacity than albumin levels measured by the traditional and less specific dye-binding method. We suggest that the immunospecific method be routinely used for determining plasma albumin levels in protein binding studies. We thank the staff of the Clinical Chemistry Department at the Royal Hobart Hospital for their assistance, and Miss H. Lawler for typing the manuscript. References DeMonaco, H. J. & Lawless, L. M. (1983). Variability of phenytoin protein binding in epileptic patients. Arch. Neurol., 40, Kilpatrick, C. J., Wanwimoiruk, S. & Wing, L. M. H. (1984). Plasma concentrations of unbound phenytoin in the management of epilepsy. Br. J. clin. Pharmac., 17, Levy, R. H. & Moreland, T. A. (1984). Rationale for monitoring free drug levels. Clin. Pharmacokin., 9 (Suppl. 1), 1-9. Perucca, E. (1984). Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies. Clin. Pharmacokin., 9 (Suppl. 1), Peterson, G. M., McLean, S., Aldous, S., von Witt,
5 R. J. & Millingen, K. S. (1982). Plasma protein binding of phenytoin in 100 epileptic patients. Br. J. clin. Pharmac., 14, Rimmer, E. M., Buss, D. C., Routledge, P. A. & Richens, A. (1984). Should we routinely measure free plasma phenytoin concentration? Br. J. clin. Pharmac., 17, Walther, H. & Meyer, F. P. (1979). Interindividual differences of protein binding in man. Int. J. clin. Short report 697 Pharmac. Biopharm., 17, Yacobi, A., Lampman, T. & Levy, G. (1977). Frequency distribution of free warfarin and free phenytoin fraction values in serum of healthy human adults. Clin. Pharmac. Ther., (Received August 21, 1984, accepted November 16, 1984)
Plasma concentrations of unbound phenytoin
Br. J. clin. Pharmac. (1984), 17, 539-546 Plasma concentrations of unbound phenytoin in the management of epilepsy C. J. KILPATRICK', S. WANWIMOLRUK2* & L. M. H. WING2 'Departments of Medicine and 2Clinical
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More informationA Theoretical Method for Normalizing Total Serum Valproic Acid Concentration in Hypoalbuminemic Patients
J Pharmacol Sci 97, 489 493 (2005) Journal of Pharmacological Sciences 2005 The Japanese Pharmacological Society Full Paper A Theoretical Method for Normalizing Total Serum Valproic Acid Concentration
More informationTherapeutic drug monitoring in epilepsy treatment
Therapeutic drug monitoring in epilepsy treatment Published Jun 24, 1998 Version 1 Findings by SBU Alert Drug monitoring as a means to adapt the dosage of antiepileptic drugs to achieve a particular concentration
More informationAdjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes
Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook
More informationReversal by phenytoin of carbamazepine-induced
Journal of Neurology, Neurosurgery, and Psychiatry, 1980, 43, 540-545 Reversal by phenytoin of carbamazepine-induced water intoxication: a pharmacokinetic interaction E PERUCCA AND A RICHENS From the Clinical
More informationTOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER)
divalproex sodium TOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER) Pharmacodynamics study of what a drug does to the body Divalproex sodium is chemically compounded from sodium valproate and
More informationDisopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases
Br. J. clin. Pharmac. (1987), 24, 199-26 Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases H. ECHIZEN', S. SAIMA2 & T. ISHIZAKI'
More informationlevetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd 11 January 2008 The Scottish Medicines
More informationThe disposition of primidone in elderly patients
Br. J. clin. Pharmac. (1990), 30, 607-611 The disposition of primidone in elderly patients C. MARTINESl*, G. GATTIl, E. SASS02, S. CALZETIT2 & E. PERUCCA' 'Clinical Pharmacology Unit, Department of Internal
More informationOF WARFARIN AT STEADY STATE
Br J clin Pharmac (1979), 8, 243-247 PHARMACOKNETCS AND PHARMACODYNAMCS OF WARFARN AT STEADY STATE PA ROUTLEDGE, PH CHAPMAN, DM DAVES & MD RAWLNS Department of Pharmacological Sciences, Wolfson Unit of
More informationeven more potent than quinine (White, 1985), is also gaining wide use (Phillips et al., 1985). The binding of quinine and quinidine to
Br. J. clin. Pharmac. (1987), 24, 769-774 Differences in the binding of quinine and quinidine to plasma proteins GEORGE W. MIHALY, MICHAEL S. CHING, MARGARET B. KLEJN, JOHN PAULL' & RICHARD A. SMALLWOOD
More informationPHENYTOIN DOSING INFORMATION. Adult Dosage
PHENYTOIN DRUGDEX Evaluations DOSING INFORMATION Adult Dosage Normal Dosage Important Note ) Due to the risk of severe hypotension and cardiac arrhythmias, the rate of IV phenytoin administration should
More informationpossible that in some epileptic patients treated with carbamazepine the signs of water intoxication are mistakenly attributed to direct drug toxicity
Journsal ofneurology, Neurosurgery, and Psychiatry, 1978, 41, 713-718 Water intoxication in epileptic patients receiving carbamazepine E. PERU CCA, A. GARRATT, S. HEBDIGE, AND A. RICHENS From the Chalfont
More informationValproic acid. Brand Name: Depakene Drug Class: Opportunistic Infection and Other Drugs
Brand Name: Depakene Drug Class: Opportunistic Infection and Other Drugs Drug Description Valproic acid is a carboxylic acid that increases gamma-amino butyric acid (GABA) levels in the central nervous
More informationSingle dose pharmacokinetic study of clobazam in normal
Br. J. clin. Pharmac. (1984), 18, 873-877 Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients S. JAWAD & A.. RICHS Department of Pharmacology and Therapeutics, Welsh
More informationTHE OUTCOMES OF PREGNANCY IN WOMEN WITH UNTREATED EPILEPSY
Title: THE OUTCOMES OF PREGNANCY IN WOMEN WITH UNTREATED EPILEPSY Author: FJE. Vajda T.J. O Brien J. Graham C.M. Lander MJ. Eadie PII: S1059-1311(14)00236-2 DOI: http://dx.doi.org/doi:10.1016/j.seizure.2014.08.008
More informationValproate Case 1: Pharmacokinetics Jose de Leon, MD
Valproate Case 1: Pharmacokinetics 2-12-16 Jose de Leon, MD 1. Valproate Case 1 J Clin Psychopharmacology 2009;29:509-11 http://www.ncbi.nlm.nih.gov/pubmed/19745660 Educational Objectives At the conclusion
More informationPHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.
PHA 58 ase Study 4 (Answers) Spring 4. PT is a patient stabilized on chronic phenytoin therapy. She has just been diagnosed with rheumatoid arthritis and her physician would like to start her on high dose
More informationTDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:
Lecture 9: Very important supplements TDM Effect of hepatic disease on drugs monitoring: Generally, hepatic clearance is determined by three main factors: - Liver blood flow (LBF). - Intrinsic capacity
More informationSang Ling Wu, MD, Wei Li, MD, PhD, Alice Wells, MT(ASCP), and Amitava Dasgupta, PhD
Clinical Chemistry / DIGOXIN-LIKE AND DIGITOXIN-LIKE IMMUNOREACTIVE SUBSTANCES IN ELDERLY PEOPLE Digoxin-Like and Digitoxin-Like Immunoreactive Substances in Elderly People Impact on Therapeutic Drug Monitoring
More informationEpilepsy and EEG in Clinical Practice
Mayo School of Professional Development Epilepsy and EEG in Clinical Practice November 10-12, 2016 Hard Rock Hotel at Universal Orlando Orlando, FL Course Directors Jeffrey Britton, MD and William Tatum,
More informationChapter 31-Epilepsy 1. public accountant, and has begun treatment with lamotrigine. In which of the following activities
Chapter 31-Epilepsy 1 Chapter 31. Epilepsy, Self-Assessment Questions 1. BW is a 28-year-old man recently diagnosed with partial seizures. He works as a certified public accountant, and has begun treatment
More informationThe excretion of zopiclone into breast milk
Br. J. clin. Pharmac. (1990), 30, 267-271 The excretion of zopiclone into breast milk I. MATHESON1, H. A. SANDE2 & J. GAILLOT3 'Department of Pharmacotherapeutics, University of Oslo, Oslo, 2Department
More informationUsing the BNF. CWFS F1 Programme Safe Prescribing Module
Using the BNF CWFS F1 Programme Safe Prescribing Module Know Your BNF Guidance on prescribing - Controlled drugs and dependence - Prescribing in palliative care/elderly/children Emergency treatment of
More informationEPILEPSY SUPPORT ASSOCIATION UGANDA
INFO PAGE 2 MEDICAL MANAGEMENT OF EPILEPSY MEDICATION FOR EPILEPSY The standard modern treatment for epileptic seizures is the regular use of one or more chemical substances called anti-convulsant or anti-epileptic
More informationINDIVIDUALVARIATION IN DAILY DOSAGE REQUIREMENTS FOR
Br.J. clin. Pharmac. (1978),,7-71 INDIVIDUALVARIATION IN DAILY DOSAGE REQUIREMENTS FOR PHENYTOIN SODIUM IN PATIENTS WITH EPILEPSY M.H. BAROT & R.H.E. GRANT David Lewis Centre for Epilepsy, Alderley Edge,
More informationNinlaro. (ixazomib) New Product Slideshow
Ninlaro (ixazomib) New Product Slideshow Introduction Brand name: Ninlaro Generic name: Ixazomib Pharmacological class: Proteasome inhibitor Strength and Formulation: 2.3mg, 3mg, 4mg; gel caps Manufacturer:
More informationDrug combinations and impaired renal function the triple whammy
DOI:10.1111/j.1365-2125.2004.02188.x British Journal of Clinical Pharmacology Drug combinations and impaired renal function the triple whammy Katarzyna K. Loboz & Gillian M. Shenfield 1 Department of Pharmacology,
More informationMedications for Epilepsy What I Need to Know
Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for
More informationNOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT
More informationphenytoin, carbamazepine or sodium valproate attending an
Postgraduate Medical Journal (1987) 63, 841-845 The effective evaluation of thyroid status in patients on phenytoin, carbamazepine or sodium valproate attending an epilepsy clinic A.A. Connacher, D.Q.
More informationWhat is the lowest dose of depakote
What is the lowest dose of depakote The Borg System is 100 % What is the lowest dose of depakote Oral dosage (delayed-release divalproex (Depakote), valproic acid (Depakene), or delayed-release valproic
More informationPHARMACEUTICAL INFORMATION AZILSARTAN
AZEARLY Tablets Each Tablet Contains Azilsartan 20/40/80 mg PHARMACEUTICAL INFORMATION AZILSARTAN Generic name: Azilsartan Chemical name: 2-Ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-
More informationEpilepsy is a very individualized
... PRESENTATION... Treatment of Epilepsy in 3 Specialized Populations Based on a presentation by Ilo E. Leppik, MD Presentation Summary When discussing the treatment of epilepsy, targeted populations
More informationONFI (clobazam) oral suspension and tablet
ONFI (clobazam) oral suspension and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationDoses Target Concentration Intervention
1 Doses Target Concentration Intervention 2 Problem 1 Questions 1-2 Susan is a 28 year old woman who has had epilepsy since she was 5 years old. She has been on, and off, anticonvulsant medication since
More informationeslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd
eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd 8 October 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationShared Care Guidance. Vigabatrin
North of Tyne Area Prescribing Committee Shared Care Guidance Vigabatrin July 2014 (Review date July 2016) This guidance has been prepared and approved for use in Newcastle, North Tyneside and Northumberland.
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationPhenytoin and postoperative epilepsy
J Neurosurg 58:672-677, 1983 Phenytoin and postoperative epilepsy A double-blind study J. BRIAN NORTIt, F.R.A.C.S., ROBERT K. PENHALL, F.R.A.C.P., AttMAD HANIEH, F.R.A.C.S., DEREK B. FREWIN, F.R.A.C.P.,
More informationTRANSPARENCY COMMITTEE OPINION. 19 July 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated
More informationCLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES
National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) CP11 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION The
More informationConcomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Concomitant administration of rifampicin and oxcarbazepine results in
More informationThe effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics
Br. J. clin. Pharmac. (1984), 18, 393-400 The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics T. K. DANESHMEND* & C. J. C. ROBERTS University Department of Medicine, Bristol
More informationCLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES
National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) MMCP05 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION
More informationI. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs)
1 2 I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationBasic Principles in Pharmacology
L. 1 Dr. Mohammed AL-Zobaidy Basic Principles in Pharmacology Learning objectives: by the end of this lecture you should Understand the possible uses of drugs. Explain why a drug has different names. Identify
More informationValproate Case 3: Formulations Jose de Leon, MD
Valproate Case 3: Formulations 2-12-16 Jose de Leon, MD 3.Valproate Case 3 Described in J Clin Psychiatry 2004;65:724-5 http://www.ncbi.nlm.nih.gov/pubmed/15163266 Pharmacological explanation provided
More informationSERUM PHENYTOIN CONCENTRATION AND CLINICAL
Br. J. clin. Pharmac. (1981), 12, 833-8 SERUM PHENYTOIN CONCENTRION AND CLINICAL RESPONSE IN PIENTS WITH EPILEY D.J. GANNAWAY & G.E. MAWER Department of Pharmacology, Materia Medica & Therapeutics, University
More informationEpidiolex (cannabidiol) NEW PRODUCT SLIDESHOW
Epidiolex (cannabidiol) NEW PRODUCT SLIDESHOW Introduction Brand name: Epidiolex Generic name: Cannabidiol Pharmacological class: Cannabinoid Strength and Formulation: 100mg/mL; oral soln; strawberry-flavored;
More informationClinical Pharmacology and Prescribing
1 Clinical Pharmacology and Prescribing Dr Susannah O Sullivan Department of Pharmacology 2 Objectives Recognise the importance of clinical pharmacology as the scientific discipline that underpins a rational
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Chronic lymphocytic leukaemia 1 Chronic lymphocytic leukemia (CLL) is a condition characterized by a progressive accumulation
More informationimproving the patient s quality of life.
Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity of seizures in
More informationEffects of Liver Disease on Pharmacokinetics
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 31, 2013 National Institutes of Health Clinical Center 1 GOALS of Effects of Liver
More informationVI.2 Elements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Product therapeutic indications: Myocardial infarction is the medical term for an event commonly known as a heart attack. It happens
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN 2 RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMIZE OR FURTHER CHARACTERISE THE RISKS
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for Briviact This is a summary of the risk management plan (RMP) for Briviact. The RMP details important risks of Briviact,
More informationInt.J.Curr.Res.Aca.Rev.2016; 4(7): 32-37
Evaluation of Clinical Outcome, Drug Utilization and Effect on Liver Enzymes of Anti-epileptics in Epileptic Patients Mathew George 1, Lincy Joseph 2, Robert Mathew 3 and Preethi Christina Jose 4 * 1 Department
More informationDefining refractory epilepsy
Defining refractory epilepsy Pasiri S, PMK Hospital @ 8.30 9.00, 23/7/2015 Nomenclature Drug resistant epilepsy Medically refractory epilepsy Medical intractable epilepsy Pharmacoresistant epilepsy 1 Definition
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationfor adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services
The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service
More informationNew antiepileptic drugs
Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont
More informationCLINICIAN INTERVIEW AS i M: When you examine a clinical trial in new- onset epilepsy, how relevant are the results to your daily clinical practice?
FROM CLINICAL TRIALS TO CLINICAL PRACTICE: TRANSLATING EPILEPSY RESEARCH INTO PATIENT CARE Interview with Jacqueline A. French, MD Dr Jacqueline A. French is a Professor in the Department of Neurology
More informationEpilepsy in a children's hospital: an out-patient survey
Seizure 1995; 4:279-285 Epilepsy in a children's hospital: an out-patient survey A.P. HUGHES & R.E. APPLETON Roald Dahl E.E.G. Unit, Royal Liverpool Children's NHS Trust Address for correspondence: Dr
More informationDefinition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors:
INDICATION High grade lymphoma with high risk of CNS involvement Definition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors: Age > 60 Raised serum
More informationEffects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National Institutes of Health Clinical Center GOALS of Liver Disease
More informationAUSTRALIAN PRODUCT INFORMATION EPILIM IV (SODIUM VALPROATE) POWDER FOR INJECTION 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
AUSTRALIAN PRODUCT INFORMATION EPILIM IV (SODIUM VALPROATE) POWDER FOR INJECTION 1 NAME OF THE MEDICINE Sodium valproate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Epilim IV Powder for Injection is presented
More informationEFFECTS OF MICROSOMAL ENZYME INDUCTION ON PARACETAMOL METABOLISM IN MAN
Br. J. clin. Pharmac. (1981),12,149-153 EFFECTS OF MICROSOMAL ENZYME INDUCTION ON PARACETAMOL METABOLISM IN MAN L.F. PRESCOT, J.A.J.H. CRITCHLEY, M. BALALI-MOOD & B. PENTLAND University Departments of
More informationEffects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National Institutes of Health Clinical Center GOALS of Liver Disease
More informationPRAZOSIN PROTEIN BINDING IN HEALTH AND DISEASE
Br. J. clin. Pharmac. (1980), 9, 177-182 PRAZOSIN PROTEIN BINDING IN HEALTH AND DISEASE P. RUBIN* & T. BLASCHKE Division of Clinical Pharmacology, Stanford University Medical Center, California 94305,
More informationAuthorised: JSWoodford, Lead of Speciality. Biochemistry Reference Intervals, October Page 1 of 5
AFP All All < 15 ug/l Albumin All 0-3M 25-40 g/l Albumin All 3-12M 32-45 g/l Albumin All 1-70Y 34-48 g/l Albumin All >70Y 32-46 g/l Alk Phos All 0-10Y 80-350 U/L Alk Phos M 10-14Y 45-400 U/L Alk Phos F
More informationTHE TREATMENT GAP AND POSSIBLE THERAPIES OF EPILEPSY IN SUB- SAHARAN AFRICA
THE TREATMENT GAP AND POSSIBLE THERAPIES OF EPILEPSY IN SUB- SAHARAN AFRICA DR A.O. CHARWAY-FELLI, MD, PhD NEUROLOGIST 37 MILITARY HOSPITAL, ACCRA, GHANA SECRETARY-GENERAL AFRICAN ACADEMY OF NEUROLOGY
More informationChapter 6 PHARMACOVIGELANCE. M.G.Rajanandh, Department of Pharmacy Practice, SRM College of Pharmacy, SRM University.
Chapter 6 PHARMACOVIGELANCE M.G.Rajanandh, Department of Pharmacy Practice, SRM College of Pharmacy, SRM University. DEFENITION: Pharmacovigilance (abbreviated PV or PhV) is the Pharmacological science
More informationXtandi (enzalutamide) NEW INDICATION REVIEW
Xtandi (enzalutamide) NEW INDICATION REVIEW Introduction Brand name: Xtandi Generic name: Enzalutamide Pharmacological class: Androgen receptor inhibitor Strength and Formulation: 40mg; soft gelatin caps
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationSub Population: The elderly
Sub Population: The elderly How can Modelling and Simulation inform understanding of safety and efficacy? Amy S. Y. Cheung, Senior Clinical Pharmacometrician Early Clinical Development, AstraZeneca On
More informationLeucovorin Calcium Tablets USP, 5 mg, 10 mg, 15 mg, and 25 mg
Leucovorin Calcium Tablets USP, 5 mg, 10 mg, 15 mg, and 25 mg Rx only DESCRIPTION Leucovorin Calcium Tablets USP contain either 5 mg, 10 mg, 15 mg or 25 mg leucovorin as the calcium salt of N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]
More informationSummary Clinical Evaluation of Carisbamate for Adjunctive Use in Treatment of Partial Onset Seizures
Summary Clinical Evaluation of Carisbamate for Adjunctive Use in Treatment of Partial Onset Seizures J&J Pharmaceutical R&D Antiepileptic Drug Trials XI April 27 2011 Summary of Past Development Efficacy
More informationThe Epilepsy Prescriber s Guide to Antiepileptic Drugs
The Epilepsy Prescriber s Guide to Antiepileptic Drugs The Epilepsy Prescriber s Guide to Antiepileptic Drugs Philip N. Patsalos FRCPath, PhD Professor of Clinical Pharmacology and Consultant Clinical
More informationDEPAKOTE ER DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS R x Only
Page 1 (No. 3826 and, 7126) 03-5235-R4-Rev. December, 2002 NEW DEPAKOTE ER DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS R x Only BOX WARNING: HEPATOTOXICITY: HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED
More informationOspolot Sulthiame 50mg and 200mg Tablets
NAME OF THE MEDICINE Sulthiame Sulthiame 50mg and 200mg Tablets Chemical name: 4-(Tetrahydro-2H-1,2-thiazin-2-yl)benzenesulfonamide- S,S-dioxide The molecular weight of the compound is 290.4 and the CAS
More informationClodronate BE/H/PSUR/001/001 October 2011 Agreed CSP
Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Intravenous use Treatment of hypercalcemia due to malignancy. Oral use Treatment of hypercalcemia
More informationIngrezza. (valbenazine) New Product Slideshow
Ingrezza (valbenazine) New Product Slideshow Introduction Brand name: Ingrezza Generic name: Valbenazine Pharmacological class: Vesicular monoamine transporter 2 (VMAT2) inhibitor Strength and Formulation:
More informationManagement of Epilepsy in Older People Christine J Kilpatrick, Adrian J Lowe
REGERIATRIC THERAPEUTICS Editors: Dr Michael Woodward, Director of Aged Care Services, Dr Juli Moran, Consultant Geriatrician, Dr Margaret Bird, Consultant Geriatrician, Mr Rohan Elliott, Clinical Pharmacist,
More informationNMIH 206 NOTES TOPIC. Page 1 of 5
NMIH 206 NOTES TOPIC PAGE NUMBER PHARMACOKINETICS 2-15 INFECTIONS & VACCINATIONS 16-18 ANTICOAGULANT & CLOTTING TIMES 19-24 CARDIAC DRUGS: ANGININE & LANOXIN 25-27 ANAESTHETICS 28-31 NUTRITION 36-40 HYPOLIPIDAEMIC
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationPackage leaflet: Information for the patient. ETOPOPHOS 100 mg Powder for Solution for Injection Etoposide phosphate
Package leaflet: Information for the patient ETOPOPHOS 100 mg Powder for Solution for Injection Etoposide phosphate Read all of this leaflet carefully before you start taking this medicine because it contains
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationChallenging epilepsy with antiepileptic pharmacotherapy in a tertiary teaching hospital in Sri Lanka
Original Article Challenging epilepsy with antiepileptic pharmacotherapy in a tertiary teaching hospital in Sri Lanka S. H. Kariyawasam, Namal Bandara,* A. Koralagama,** Sunethra Senanayake*** Dept. of
More informationThe Effectiveness of Monotheraby in Epileptic Sudanese Patients
The Effectiveness of Monotheraby in Epileptic Sudanese Patients Amel Elmahi Mohamed (1) Sawsan A Aldeaf (1) Alsadig Gassoum (1) Alnada Abdalla Mohamed (2) Mohamed A Arbab (1,3) and Alamin Ebrahim (2) Abstract
More informationMANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM
MANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM Are Particular Anti-hypertensives More Effective or Harmful Than Others in Hypertension in Pregnancy? Existing data is inadequate Methyldopa and
More informationNUMERATOR: Female patients or caregivers counseled at least once a year about how epilepsy and its treatment may affect contraception OR pregnancy
Quality ID #268 (NQF 1814): Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationTaking the guesswork out of supplying multi-compartment compliance aids: do pharmacists
1 2 Taking the guesswork out of supplying multi-compartment compliance aids: do pharmacists require further guidance on medication stability? 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
More informationTHE SPECIALIST NURSE INTERVENTION: PROMOTING UNDERSTANDING. Marianne Peachey Epilepsy Specialist Nurse The Ipswich Hospital NHS Trust
THE SPECIALIST NURSE INTERVENTION: PROMOTING UNDERSTANDING Epilepsy Specialist Nurse The Ipswich Hospital NHS Trust NURSING Is it Art or Science? Hospital Consultants General Practitioners Hospital Nursing
More informationComparison of the efficacy and tolerance of isoxicam and piroxicam following surgery for skiing accidents
Br. J. clin. Pharmac. (1986), 22, 161S-165S Comparison of the efficacy and tolerance of isoxicam and piroxicam following surgery for skiing accidents P. MASSART & 'H. BEZES Clinique Chirurgicale et Traumatologique
More informationBasics of TDM with example drugs
Basics of TDM with example drugs Pharmacokinetic differences in drug handling between patients produce wide variability in serum drug concentrations, but dosage adjustments are generally only required
More informationNICE guidelines. Type 2 diabetes in adults: management
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE NICE guidelines Equality impact assessment Type 2 diabetes in adults: management The impact on equality has been assessed during guidance development according
More informationDoes the Use of Ultrafiltration Increase the Risk of Post-Operative Acute Kidney Injury? A Multi-Center Analysis
Does the Use of Ultrafiltration Increase the Risk of Post-Operative Acute Kidney Injury? A Multi-Center Analysis Gordon R. DeFoe, CCP, John Pieroni, CCP, Craig S. Warren, CCP, Charles F. Krumholz, CCP,
More information